FROVATRIPTAN SUCCINATE (frovatriptan succinate) by Ichnos Glenmark Innovation is 5-ht 1b/1d receptors. Approved for migraine attacks, cluster headache (), migraine. First approved in 2016.
Drug data last refreshed 18h ago
5-HT 1B/1D receptors. The therapeutic activity of frovatriptan is thought to be due to the agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and…
Worked on FROVATRIPTAN SUCCINATE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.